Reports Q3 revenue $62.175M, consensus $34.19M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Our U.S. launch of Rezdiffra is progressing exceptionally well driven by the outstanding execution of our team. Growing adoption by prescribers, broader payer coverage and an increasing number of patients on therapy each contributed to the strong performance. This early success highlights the critical need for effective treatments for moderate to advanced NASH/MASH, which is expected to become the leading cause of liver transplants in the U.S.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals to present multiple resmetirom data presentations
- MDGL Upcoming Earnings Report: What to Expect?
- Madrigal Pharmaceuticals price target lowered to $350 from $375 at Oppenheimer
- 3 Best Stocks to Buy Now, 10/23/2024, According to Top Analysts
- Madrigal Pharmaceuticals completes enrollment of study of Resmetirom